Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis

Oncogene

Volumn 27, Issue 9, 2008, Pages 1218-1230

  Gal, A ^a,b   Sjoblom T ^a,d   Fedorova, L ^c   Imreh, S ^c   Beug, H ^b   Moustakas, A ^a,e  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Epithelial mesenchymal transition; Metastasis; Signal transduction; Smad; TGF ; Tumour suppression

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL TRANSFORMATION; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETINAE; CRICETULUS; EPITHELIAL CELLS; FEMALE; GENES, TUMOR SUPPRESSOR; MAMMARY GLANDS, ANIMAL; MESODERM; MICE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 39749157093     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210741     Document Type: Article

References (26)

1. Balkwill F. (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
2. Dalal BI, Keown PA, Greenberg AH. (1993). Immunocytochemical localization of secreted transforming growth factor-β 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389.
3. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P et al. (2001). Transforming growth factor β signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFβ signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 502: 4-10.
4. Feng X-H, Derynck R. (2005). Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693.
5. Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, Schulte-Hermann R et al. (2002). Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-β1 and Ha-Ras: steps towards invasiveness. J Cell Sci 115: 1189-1202.
6. Grünert S, Jechlinger M, Beug H. (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665.
7. Huber MA, Kraut N, Beug H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558.
8. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L et al. (2007). p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39: 741-749.
9. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. (1995). Elevated plasma levels of TGF-β 1 in patients with invasive prostate cancer. Nat Med 1: 282-284.
10. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. (2002a). Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156: 299-313.
11. Janda E, Litos G, Grünert S, Downward J, Beug H. (2002b). Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway. Oncogene 21: 5148-5159.
12. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P et al. (2006). Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570.
13. Kowanetz M, Valcourt U, Bergström R, Heldin C-H, Moustakas A. (2004). Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. Mol Cell Biol 24: 4241-4254.
14. Levy L, Hill CS. (2006). Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58.
15. Massagué J, Gomis RR. (2006). The logic of TGFβ signaling. FEBS Lett 580: 2811-2820.
16. Moustakas A, Heldin C-H. (2005). Non-Smad TGF-β signals. J Cell Sci 118: 3573-3584.
17. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. (1996). TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477.
18. Pardali K, Moustakas A. (2007). Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62.
19. Piek E, Heldin C-H, ten Dijke P. (1999a). Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13: 2105-2124.
20. Piek E, Moustakas A, Kurisaki A, Heldin C-H, ten Dijke P. (1999b). TGF-β type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112(Part 24): 4557-4568.
21. Roberts AB, Wakefield LM. (2003). The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
22. Shim KS, Kim KH, Han WS, Park EB. (1999). Elevated serum levelsof transforming growth factor-β1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 85: 554-561.
23. Siegel PM, Massagué J. (2003). Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
24. Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E et al. (2001). Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783.
25. Thiery JP, Sleeman JP. (2006). Complex networksorc hestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
26. Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T et al. (2006). Interleukin-like EMT Inducer (ILEI): new cytokine essential for EMT, tumor formation and late events in metastasis in epithelial cells. Cancer Cell 10: 227-239.